ARTICLE | Company News
Gamida, Editas to use CRISPR in NAM-NK cells
February 21, 2019 11:50 PM UTC
Editas Medicine Inc. (NASDAQ:EDIT) and Gamida Cell Ltd. (NASDAQ:GMDA) partnered to optimize NK cells from Gamida to treat hematologic malignancies and solid tumors. The partners will evaluate undisc...